The Georgia State University preclinical work on oral GHP-88310, reported in Science Advances, demonstrates once-daily efficacy against human parainfluenza virus type 3 and measles in rodent and non-rodent models plus human airway organoids. This is not an RCT; the study relies on animal infection models without reported human dosing data, and sample sizes remain modest by clinical standards. No conflicts of interest are disclosed in the primary report. Mainstream coverage fixates on the compound's convenience and safety margin while missing the larger pattern: decades of antiviral investment have produced narrow agents (remdesivir for SARS-CoV-2, oseltamivir for influenza) that leave paramyxovirus families largely untouched despite recurrent measles outbreaks in under-vaccinated U.S. regions and rising henipavirus spillover risks. A 2023 Lancet Infectious Diseases review of paramyxovirus therapeutics highlighted the same therapeutic gap that GHP-88310 now targets, noting zero approved small-molecule options for parainfluenza pneumonia in transplant recipients—an estimated three million U.S. cases annually. The compound's high barrier to escape mutants in animals echoes earlier successes with broad nucleoside analogs but contrasts with the rapid resistance seen in COVID protease inhibitors. If translated to humans, this could reduce reliance on supportive care alone for immunocompromised children and older adults, yet the absence of phase 1 safety data leaves the wide therapeutic index unproven in vulnerable populations. The work also quietly reframes croup management, historically viral and self-limited, as a potential antiviral indication where current steroids address only inflammation.